Clinical Research Directory

Inclusion Criteria: 1. Aged 18-65 years; 2. Meeting the diagnostic criteria for metabolic-associated steatohepatitis (MASH) and the traditional Chinese medicine syndrome differentiation criteria for dampness-heat accumulation pattern; 3. Initial treatment for H. pylori infection (positive 13C- or 14C-urea breath test); 4. Signed informed consent form. Exclusion Criteria: 1. Individuals with fatty liver caused by chronic heart failure, malnutrition, or pregnancy; those with fatty liver syndrome in encephalopathy, abetalipoproteinemia, or localized fatty liver; 2. Patients with severe fatty liver accompanied by ascites, edema, hyponatremia, hypokalemia, or other signs suggestive of cirrhosis; those with hepatitis or cirrhosis caused by viruses, drug toxicity, autoimmune diseases, or other factors; 3. Individuals using hepatoprotective, enzyme-lowering, or lipid-lowering medications that may interfere with efficacy evaluation; 4. Pregnant or lactating women; 5. Patients with severe primary cardiovascular, renal, or other life-threatening diseases; 6. Individuals with a history of cancer; 7. Those positive for HCV antibody, HIV antibody, or HBsAg with detectable HBV-DNA levels; 8. Individuals with a history of alcohol abuse (≥210 g/week for males or ≥140 g/week for females) or substance abuse; 9. Those with known hypersensitivity to any component of the study drug; 10. Participation in another clinical trial within 3 months prior to screening; 11. Use of Chinese herbal medicines for the treatment of non-alcoholic simple fatty liver within 2 weeks prior to screening; 12. Individuals deemed unsuitable for participation by the investigator.